PART I Overview We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The a...
Q2 FY2026 — expected 2026-09-20
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | GRCE | discussed_in_filing Artificial Intelligence | |
| topic_mention | GRCE | discussed_in_filing Trusted Computing | |
| topic_mention | GRCE | discussed_in_filing Blockchain & Crypto | |
| topic_mention | GRCE | discussed_in_filing Regulation | |
| topic_mention | GRCE | discussed_in_filing Healthcare & Bio | |
| topic_mention | GRCE | discussed_in_filing Sovereign & Government | |
| topic_mention | GRCE | discussed_in_filing Artificial Intelligence | |
| topic_mention | GRCE | discussed_in_filing Trusted Computing | |
| topic_mention | GRCE | discussed_in_filing Blockchain & Crypto | |
| topic_mention | GRCE | discussed_in_filing Regulation | |
| topic_mention | GRCE | discussed_in_filing Healthcare & Bio | |
| topic_mention | GRCE | discussed_in_filing Sovereign & Government | |
| topic_mention | GRCE | discussed_in_filing Artificial Intelligence | |
| topic_mention | GRCE | discussed_in_filing Trusted Computing | |
| topic_mention | GRCE | discussed_in_filing Blockchain & Crypto | |
| topic_mention | GRCE | discussed_in_filing Regulation | |
| topic_mention | GRCE | discussed_in_filing Healthcare & Bio | |
| topic_mention | GRCE | discussed_in_filing Sovereign & Government | |
| topic_mention | GRCE | discussed_in_filing Artificial Intelligence | |
| topic_mention | GRCE | discussed_in_filing Trusted Computing |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-06-23 | 2025-03-31 | 0001140361-25-023259 | EDGAR | 61K words |
| 2024-06-21 | 2024-03-31 | 0000950170-24-075875 | EDGAR | — |
| 2023-06-23 | 2023-03-31 | 0000950170-23-029498 | EDGAR | — |
| 2022-06-21 | 2022-03-31 | 0000950170-22-011842 | EDGAR | — |
| 2021-06-22 | 2021-03-31 | 0001171843-21-004462 | EDGAR | — |
| 2020-06-29 | 2020-03-31 | 0001171843-20-004613 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001140361-26-004924 | EDGAR | 23K words |
| 2025-11-13 | 2025-09-30 | 0001140361-25-041804 | EDGAR | — |
| 2025-08-12 | 2025-06-30 | 0001140361-25-030398 | EDGAR | — |
| 2025-02-13 | 2024-12-31 | 0001140361-25-004153 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001140361-24-046312 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0000950170-24-094348 | EDGAR | — |
| 2024-02-12 | 2023-12-31 | 0000950170-24-013566 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062437 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041595 | EDGAR | — |
| 2023-02-14 | 2022-12-31 | 0000950170-23-002695 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024666 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016632 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-12 | 0001140361-26-004927 | EDGAR | 4K words |
| 2026-01-12 | 0001140361-26-000995 | EDGAR | — |
| 2025-11-13 | 0001140361-25-041807 | EDGAR | — |
| 2025-10-23 | 0001140361-25-039020 | EDGAR | — |
| 2025-09-18 | 0001140361-25-035337 | EDGAR | — |
| 2025-09-12 | 0001140361-25-034845 | EDGAR | — |
| 2025-08-27 | 0001140361-25-032847 | EDGAR | — |
| 2025-08-12 | 0001140361-25-030400 | EDGAR | — |
| 2025-06-25 | 0001140361-25-023557 | EDGAR | — |
| 2025-06-23 | 0001140361-25-023261 | EDGAR | — |
362 total filings indexed. 334 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001444192 |
| Ticker | GRCE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report